Atley Unveils the C100

CEO Milton Lönnroth and Radiochemist Ellinor Hansson with the C100 at the TAT-12 conference

Atley’s C100 module made its first public appearance at the TAT-12 conference in Cape Town. The conference, which featured a presentation from Atley Co-Founder & Senior Radiochemist Emma Aneheim, focused on the use of Targeted Alpha Therapy for the treatment of metastatic cancers.

At the conference, the formation of the World Astatine Community was also announced, a community that Atley looks forward to collaborating with and contributing to in order to foster global astatine collaboration between both academia and industry.